Press releases
- Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation
- Pulse Biosciences, Inc. Announces the Closing of its Rights Offering
- Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
- Pulse Biosciences, Inc. Announces Commencement of Rights Offering
- Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
- Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
- Pulse Biosciences Enhances Executive Leadership Team
- Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
- Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
- Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
More ▼
Key statistics
As of last trade Pulse Biosciences Inc (6L8:DUS) traded at 15.80, -11.73% below its 52-week high of 17.90, set on Jul 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.90 |
---|---|
High | 15.90 |
Low | 15.80 |
Bid | 15.80 |
Offer | 16.20 |
Previous close | 15.10 |
Average volume | 474.56 |
---|---|
Shares outstanding | 61.23m |
Free float | 17.04m |
P/E (TTM) | -- |
Market cap | 1.07bn USD |
EPS (TTM) | -0.8152 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 11:31 BST.
More ▼